Afinitor (everolimus):

On Friday July 20th 2012 the FDA approved a new drug in the fight against breast cancer.

Afinitor (marketed by Novartis Pharmaceuticals Corp.) a drug that has been approved by the FDA to fight advanced kidney and neuroendocrine tumors, has now been approved by the FDA (Food and Drug Administration) to fight an advanced form of breast cancer known as hormone-receptor positive, HER2-negative (found in women who are postmenopausal).

According to the FDA, approval of Afinitor was based on a clinical trial involving 724 postmenopausal women with advanced breast cancer that had spread despite prior treatment with Femara, Arimidex and Aromasin.

The trial found that adding Afinitor boosted the average progression-free survival by 4.6 months.

Side Effects of Afinitor: (mostly found in women aged 65 or older)

Rash

Fatigue

Diarrhea

Loss of appetite

Mouth Ulcers

“It is exciting that there continues to be advances in treating breast cancer that are allowing patients to survive longer, even in the face of metastatic disease, the improved treatment for advanced-stage breast cancer offers women hope that a treatment to completely stabilize, or even eradicate the disease, might be achievable within their lifetime.  ” Said, Dr. Stephanie Bernik, chief of surgical oncology at lenox Hill Hospital in New York City.

For more information please contact The Maher Law Firm at 1-888-884-1507